Tangkiatkumjai Mayuree, Walker Dawn-Marie, Praditpornsilpa Kearkiat, Boardman Helen
Division of Clinical Pharmacy, Faculty of Pharmacy, Srinakharinwirot University, Nakhonnayok, 26120, Thailand.
School of Health Sciences, University of Southampton, Southampton, UK.
Clin Exp Nephrol. 2017 Jun;21(3):504-512. doi: 10.1007/s10157-016-1312-6. Epub 2016 Jul 20.
There is limited evidence of medication adherence related to progression of chronic kidney disease (CKD) worldwide. The aim of this study was to determine associations between medication adherence and the progression of CKD in outpatients with CKD.
This cohort study recruited 339 Thai patients with stages 3-5 CKD. Patients with a glomerular disease or receiving renal replacement therapy before recruitment were excluded. 295 were followed up regarding their serum creatinine, blood pressure, glycated hemoglobin, and low-density lipoprotein cholesterol over 12 months. Medication adherence was measured at baseline using the Thai version of the 8-Item Morisky Medication Adherence Scale. The primary outcome was the progression of CKD. The progression of CKD was defined as either a decline in estimated glomerular filtration rate of at least 3 ml/min/1.73 m/year or initiation of renal replacement therapy. Univariate and multivariate analyses were performed using Chi-squared tests and multiple logistic regressions.
Twenty-one percent had poor adherence. Younger patients were more likely to have poor adherence (adjusted OR 2.81, 95 % CI 1.45-5.43). Anti-hypertensive agents were the most frequently reported as not being taken (52 %). Patients with poor adherence were associated with the progression of CKD (adjusted OR 1.96, 95 % CI 1.02-3.76). Those with poor adherence were less likely to control their blood pressure, than moderate-to-high adherence group (p < 0.01).
The findings suggest that CKD patients with poor medication adherence are more likely to have progression of CKD. Health care providers should acknowledge these findings and provide effective strategies to deal with this issue.
全球范围内,关于药物依从性与慢性肾脏病(CKD)进展之间关系的证据有限。本研究旨在确定CKD门诊患者药物依从性与CKD进展之间的关联。
这项队列研究招募了339例3 - 5期CKD的泰国患者。排除入组前患有肾小球疾病或接受肾脏替代治疗的患者。295例患者在12个月内接受了血清肌酐、血压、糖化血红蛋白和低密度脂蛋白胆固醇的随访。在基线时使用泰语版的8项Morisky药物依从性量表测量药物依从性。主要结局是CKD的进展。CKD的进展定义为估计肾小球滤过率至少下降3 ml/min/1.73m²/年或开始肾脏替代治疗。使用卡方检验和多元逻辑回归进行单因素和多因素分析。
21%的患者依从性差。年轻患者更有可能依从性差(调整后的OR为2.81,95%CI为1.45 - 5.43)。抗高血压药物是最常报告未服用的药物(52%)。依从性差的患者与CKD的进展相关(调整后的OR为1.96,95%CI为1.02 - 3.76)。与中度至高度依从性组相比,依从性差的患者更不容易控制血压(p < 0.01)。
研究结果表明,药物依从性差的CKD患者更有可能出现CKD进展。医疗保健提供者应认识到这些发现,并提供有效的策略来应对这一问题。